News

Access and download our newsletters from the Newsletter Archive

 
 

As well as keeping you up to date with the latest developments within the life sciences sector, Bionow members can also post updates to the Bionow News page to promote themselves to over 300 Bionow member organisations and the UK Life Sciences sector.

Whether currently a member or not, keep up to date with all the latest news and events by registering to receive the Bionow newsletter.

Catalent announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.) of a biologics development and manufacturing facility currently under construction ...

Catalent announced the completion of a $30 million (€27 million) project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutica...

Catalent announced that, effective July 1, 2021, 97% of its electricity usage across its global network is being procured from renewable energy sources such as wind, solar, hydroelectric, an...

Catalent today announced the launch of its new OptiDose® Design Solution, a comprehensive assessment of your molecule, patient, and market. Designed to incorporate recommendations from our ...

Catalent today announced that it has been recognized by the Royal Society for the Prevention of Accidents (RoSPA) for demonstrating high health and safety standards.

The investment will allow flexible jet milling operations to be carried out at Catalent’s sites in Malvern, Pennsylvania and Dartford, U.K., under containment to a working occupational exp...

Catalent has entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therap...

Catalent today welcomed the news from Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule charged sodium channel blockers, that its first patient has been ...

T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, and Catalent, the leading global provide...

Catalent today announced that it is investing $50 million to install an additional high-speed vial filling line at its Bloomington, Indiana, facility.

Sign up to our Newsletter

Subscribe

* indicates required

Our Valued Sponsors & Partners